期刊文献+

异基因非清髓造血干细胞移植后WT1特异性T细胞亚群与移植物抗宿主病的关系 被引量:1

Relationship between WT1-specific T-cell subsets and graft-versus-host disease after nonmyeloablative allogeneic transplantation
原文传递
导出
摘要 目的探讨非清髓造血干细胞移植后WT1诱发的各T细胞亚群与移植物抗宿主病(GVHD)之间的关系。方法分析19例表达WTI的白血病患者在全相合非清髓造血干细胞移植后GVHD的发生情况;WT1126—134体外刺激患者外周血单个核细胞,采用胞内因子染色法(ICCS)检测移植前后外周血中Tc1、Tc2、Th1及Th2细胞;对供受者表达HLA—A*0201的14例患者采用HLA—A*0201/WTI五聚体检测外周血中的WT1^+CD8^+细胞毒性T淋巴细胞(CTL)。结果①19例患者中,17例并发GVHD,其中16例在GVHD发生时出现以Tc1及Th1细胞为主的高峰(P=0.039)。②Ⅱ度以上急性GVHD(aGVHD)患者在GVHD发生时Te1及Th1细胞峰值水平均高于Ⅰ度aGVHD者,但差异无统计学意义(P=0.900及P=0.140)。③弥漫型慢性GVHD(cGVHD)患耆Tc1及Th1细胞峰值水平明显高于局限型cGVHD者,但仅Th1细胞峰值水平差异具有统计学意义(P=0.004),而Tc1细胞峰值水平差异无统计学意义(P=0.060)。④未并发GVHD者Tc1、Th1及WT1^+CD8^+CTL峰值水平接近于轻度aGVHD患者的平均水平,但低于中重度aGVHD患者的平均水平。结论GVHD发生时WT1诱发的移植物抗白血病(GVL)效应增强,其强度与GVHD尤其是cGVHD发生的严重程度相关;相对于局限型cGVHD患者,弥漫型cGVHD患者WT1诱发GVL效应的增强可能与Th1细胞有关。 Objective To explore the relationship between WT1-induced T-cell subsets and graftversus-host disease(GVHD) after nonmyeloablative allogeneic hematopoietic stem cell transplantation(NST). Methods Peripheral blood mononucleated cells (PBMCs) from 19 patients who expressed WT1 and developed GVHD after NST were simulated by WT1126 - 134 peptide in vitro, and proportions of WTl-induced-T- cell subsets (Tc1 ,Tc2 ,Thl ,Th2 Cells) before and after transplant were detected by intracellular cytokine staining (ICCS) assay. WT1-specific CD8 + CTLs of 14 patients with HLA-A * 0201 were detected by HLA-A * 0201/WTI pentamer. Results (1)17 of 19 patients developed GVHD, among whom proportions of Tel and Thl cells, achieved peak value in 16 patients at occurrence of GVHD( P = 0. 039) ;(2)The peak proportions of Tcl and Thl cells in patients with aGVHD above grade Ⅱ were higher than those with grade Ⅰ , but being no statistical difference ( P = 0. 900 and P = 0. 140, respectively) ; (3)The peak proportion of Thl cells ( P = 0. 004), but not Tcl cells(P = 0. 060)in patients with extensive cGVHD was significantly higher than that in patients with limited one;(4)Proportions of Tcl, Thl and WT1 ^+ CD8 ^+ CTL in patients without GVHD were similar to those in patients with Grade Ⅰ aGVHD, but lower than those in aGVHD above grade Ⅱ. Conclusion GVHD promotes the generation of WTl-induced GVL effect, and the intensity of the latter maybe correlated with the intensity of GVHD, especially cGVHD. Thl cells play a more important role in the enhancement of WT1-induced GVL effect in extensive cGVHD patient than in limited cGVHD patients.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2011年第2期89-93,共5页 Chinese Journal of Hematology
关键词 造血干细胞移植 基因 WTI T细胞亚群 移植物白血病反应 移植物抗宿主病 Hematopoietic stem cell transplantation Whilm' s tumor gene T cell subsets Graft versus leukemia effect Graft versus host disease
  • 相关文献

参考文献13

  • 1Horowitz MM,Gale RP,Sondel PM,et al.Graft-versus-leukemia reactions after bone marrow transplantation.Blood,1990,75:555-562.
  • 2Weiden PL,Floumoy N,Thomas ED,et al.Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.N Engl J Med,1979,300:1068-1073.
  • 3Ferrara JL,Deeg HJ.Graft-versus-host disease.N Engl J Med,1991,324:667-674.
  • 4Weiden PL,Sullivan KM,Flournoy N,et al.Antileukemic effect of chronic graft-versus-host disease:contribution to improved survival after allogeneic marrow transplantation.N Engl J Med,1981,304:1529-1531.
  • 5Uzunel M,Mattsson J,Brune M,et al.Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and alogeneic stem cell transplantation.Blood,2003,101:469-472.
  • 6Fowler DH,Gress RE.CD8 + T cells of phenotype mediate a GVL effect and prevent marrow rejection.Vox Sanguinis,1998,74:331-340.
  • 7Rezvani K,Yong AS,Savani BN,et al.Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.Blood,2007,110:1924-1932.
  • 8Molldrem JJ,Lee PP,Wang C,et al.Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.Nat Med,2000,6:1018-1023.
  • 9Dickinson AM,Wang XN,Sviland L,et al.In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens.Nat Med,2002,8:410-414.
  • 10Mutis T,Gillespie G,Schrama E,et al.Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.Nat Med,1999,5:839-842.

同被引文献10

  • 1ESTEY E. AML in older patients:are we making pro- gress? [J]. Best Praet Res Clin Haematol, 2009,22: 529-536.
  • 2YANADA M, NAOE T. Acute myeloid leukemia in older adults[J]. Int J Hematol, 2012,96 : 186- 193.
  • 3BUCHNER T, BERDEL W E, HAFERLACH C, et al. Age-related risk profile and chemotherapy dose re- sponse in acute myeloid leukemia: a study by the Ger- man Acute Myeloid Leukemia Cooperative Group[J]. J Clin 0ncol,2009,27:61-69.
  • 4ZEIDAN A M, FORDE P M, SYMONS H, et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplanta- tion[J]. Biol Blood Marrow Transplant, 2014, 20: 314-318.
  • 5MORRIS E S, MACDONALD K P, HILL G R. Stem cell mobilization with G-CSF analogs: a rational ap- proach to separate GVHD and GVL? [J]. Blood, 2006,107:3430-3435.
  • 6GUO M, HU K X,YU C L,et al. Infusion of HLA mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients[J]. Blood, 2011,117 : 936 - 941.
  • 7GUO M, HU K X, LIU G X, et al. HLA-mismatchedstem-cell microtransplantation as postremission thera- py for acute myeloid leukemia: long-term follow-up [J]. J Clin Oncoi,2012,30:4084-4090.
  • 8DEY B R, MCAFEE S, COLBY C, et al. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allo- geneic stem cell transplantation[J]. Br J Haematol, 2005,128:351-359.
  • 9SPITZER T R. Microtransplantation: a new paradigm for the separation of graft versus host disease and graft versus tumor? [J]. J Clin Oncol, 2012, 30: 4051 -4052.
  • 10艾辉胜,黄晓军,乔振华,王健民,陈宝安,白海,时宝赋,梁英民,孙万军.非清髓异基因造血干细胞移植治疗血液病多中心临床报告[J].中华血液学杂志,2009,30(8):505-508. 被引量:10

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部